CA2854911C - Calcimimetics and methods for their use - Google Patents

Calcimimetics and methods for their use Download PDF

Info

Publication number
CA2854911C
CA2854911C CA2854911A CA2854911A CA2854911C CA 2854911 C CA2854911 C CA 2854911C CA 2854911 A CA2854911 A CA 2854911A CA 2854911 A CA2854911 A CA 2854911A CA 2854911 C CA2854911 C CA 2854911C
Authority
CA
Canada
Prior art keywords
seq
calcimimetic
pth
arrrar
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2854911A
Other languages
English (en)
French (fr)
Other versions
CA2854911A1 (en
Inventor
Sarah Walter
Gregory Bell
James E. Tomlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2854911(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of CA2854911A1 publication Critical patent/CA2854911A1/en
Application granted granted Critical
Publication of CA2854911C publication Critical patent/CA2854911C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2854911A 2011-11-10 2012-11-12 Calcimimetics and methods for their use Active CA2854911C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558389P 2011-11-10 2011-11-10
US61/558,389 2011-11-10
PCT/US2012/064717 WO2013071262A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Publications (2)

Publication Number Publication Date
CA2854911A1 CA2854911A1 (en) 2013-05-16
CA2854911C true CA2854911C (en) 2019-09-24

Family

ID=47258113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2854911A Active CA2854911C (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Country Status (9)

Country Link
US (3) US20140315809A1 (cg-RX-API-DMAC7.html)
EP (1) EP2776129B2 (cg-RX-API-DMAC7.html)
JP (2) JP6204369B2 (cg-RX-API-DMAC7.html)
CN (2) CN104168955A (cg-RX-API-DMAC7.html)
AU (1) AU2012335009B2 (cg-RX-API-DMAC7.html)
CA (1) CA2854911C (cg-RX-API-DMAC7.html)
HK (1) HK1202086A1 (cg-RX-API-DMAC7.html)
MX (1) MX355063B (cg-RX-API-DMAC7.html)
WO (1) WO2013071262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
HRP20171092T1 (hr) * 2013-06-28 2017-10-06 Amgen Inc. Stabilna tekuća formulacija amg 416 (velkalcetid)
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016062289A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途
EP3226891B1 (en) 2014-12-05 2025-06-25 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
JP6868561B2 (ja) * 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
HK1257341A1 (zh) 2015-08-17 2019-10-18 Alexion Pharmaceuticals, Inc. 硷性磷酸酯的制造
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CN109152820A (zh) 2016-04-01 2019-01-04 阿雷克森制药公司 用碱性磷酸酶治疗肌肉无力
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
US11450405B2 (en) * 2018-10-18 2022-09-20 Fresenius Medical Care Holdings, Inc. Techniques for modeling parathyroid gland functionality and calcimimetic drug activity
TW202122410A (zh) * 2019-12-09 2021-06-16 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物及其應用
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022052471A1 (zh) * 2020-09-10 2022-03-17 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
US20240269227A1 (en) * 2021-06-08 2024-08-15 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Calcium-sensing receptor agonist composition and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6147186A (en) * 1996-07-31 2000-11-14 The General Hospital Corporation Parathyroid hormone-related peptide analogs
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
AU2001278956B2 (en) 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
WO2003013543A1 (en) * 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
EP1858553A2 (en) * 2005-03-17 2007-11-28 Amgen Inc., Methods of decreasing calcification
JP5645408B2 (ja) 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
EP4154900B1 (en) * 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method

Also Published As

Publication number Publication date
JP2017160269A (ja) 2017-09-14
JP2015502346A (ja) 2015-01-22
AU2012335009A1 (en) 2014-05-29
CN104168955A (zh) 2014-11-26
CN109985228A (zh) 2019-07-09
MX355063B (es) 2018-04-04
US20170252397A1 (en) 2017-09-07
CA2854911A1 (en) 2013-05-16
JP6204369B2 (ja) 2017-09-27
EP2776129B1 (en) 2017-03-29
HK1202086A1 (en) 2015-09-18
EP2776129A1 (en) 2014-09-17
WO2013071262A1 (en) 2013-05-16
AU2012335009B2 (en) 2017-08-31
EP2776129B2 (en) 2020-06-17
US20140315809A1 (en) 2014-10-23
MX2014005662A (es) 2014-11-10
US20160175383A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
CA2854911C (en) Calcimimetics and methods for their use
US20250163103A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270A1 (en) Therapeutic agents for reducing parathyroid hormone levels
HK1241270B (en) Therapeutic agents for reducing parathyroid hormone levels
HK1167108B (en) Therapeutic agents for reducing parathyroid hormone levels

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170821